<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03315650</url>
  </required_header>
  <id_info>
    <org_study_id>RIVA-PCI</org_study_id>
    <nct_id>NCT03315650</nct_id>
  </id_info>
  <brief_title>Rivaroxaban in Patients With Atrial Fibrillation Undergoing PCI</brief_title>
  <acronym>RIVA-PCI</acronym>
  <official_title>RIVA-PCI Registry - Prospective Registry of Rivaroxaban in Patients With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IHF GmbH - Institut für Herzinfarktforschung</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>IHF GmbH - Institut für Herzinfarktforschung</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the antithrombotic therapy in patients suffering from atrial&#xD;
      fibrillation after stent implantation in Germany. Patients prescribed with the novel oral&#xD;
      anticoagulant Rivaroxaban will be followed up over 14 months for their adherence to the&#xD;
      medication schedule and for complications that occurred after index PCI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients suffering from non-valvular atrial fibrillation and presenting with an acute&#xD;
      coronary syndrome require special attention with regard to antithrombotic therapy. Current&#xD;
      guidelines recommend use of oral anticoagulation for almost all of these patients, the&#xD;
      optimal antithrombotic strategy, however, has still to be defined. As with the use of any&#xD;
      antithrombotic drug, clinicians need to balance the risks of ischemic stroke and&#xD;
      thromboembolism, recurrent cardiac ischemia and/or stent thrombosis, and bleeding and&#xD;
      haemorrhagic stroke.&#xD;
&#xD;
      A recently published randomized clinical trial (PIONEER AF) compared the combination of a&#xD;
      novel oral anticoagulant (NOAC; Rivaroxaban) plus dual anti-platelet therapy (DAPT) with&#xD;
      standard therapy consisting of vitamine K inhibitor plus DAPT. Patients treated with&#xD;
      Rivaroxaban showed less incidence of bleedings, whereas ischemic complications, death or&#xD;
      stroke were equal in the groups compared.&#xD;
&#xD;
      The RIVA-PCI Registry aims at providing an overview of the current antithrombotic treatment&#xD;
      regimen in Germany in real life. Moreover, for patients receiving Rivaroxaban as part of&#xD;
      their medication follow-up data with regard to their adherence to antithrombotic medication&#xD;
      as well as complications over an interval of 14 months after index procedure will be&#xD;
      evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Antithrombotic combination therapies (treatment patterns) in patients with non-valvular AF undergoing PCI</measure>
    <time_frame>18 months</time_frame>
    <description>Real-life data on the prescription of antithrombotic medication for patients with atrial fibrillation after PCI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of antithrombotic medication during long-term follow-up</measure>
    <time_frame>14 months</time_frame>
    <description>Patients receiving Rivaroxaban after index PCI are asked for their further antithrombotic medication in two telephone interviews (3 months and 14 months after index PCI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events during baseline and follow-up</measure>
    <time_frame>32 months</time_frame>
    <description>Documentation of Adverse Events during baseline hospital stay (by treating physician) and during long-term follow-up (patient-reported)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment adherence of patients</measure>
    <time_frame>14 months</time_frame>
    <description>Patient-reported information on their adherence to the antithrombotic treatment strategy</description>
  </secondary_outcome>
  <enrollment type="Actual">1632</enrollment>
  <condition>Non-valvular Atrial Fibrillation</condition>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <condition>Antithrombotic Therapy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive, unselected recruitment of patients fulfilling the eligibility criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years and capable of giving written informed consent&#xD;
&#xD;
          -  Known or newly diagnosed non-valvular atrial fibrillation&#xD;
&#xD;
          -  PCI with stent implantation during index hospital stay&#xD;
&#xD;
          -  Written informed consent for participation in observational study (incl. telephone&#xD;
             follow-up)&#xD;
&#xD;
          -  Not simultaneously participating in any randomized trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uwe Zeymer, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut für Herzinfarktforschung (Institute for Cardiac Research)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kerckhoff-Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Segeberger Kliniken</name>
      <address>
        <city>Bad Segeberg</city>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gesundheitszentrum Bitterfeld-Wolfen</name>
      <address>
        <city>Bitterfeld-Wolfen</city>
        <zip>06749</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Links der Weser</name>
      <address>
        <city>Bremen</city>
        <zip>28277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Buchholz</name>
      <address>
        <city>Buchholz</city>
        <zip>21244</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SLK-Kliniken Heilbronn</name>
      <address>
        <city>Heilbronn</city>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Ludwigshafen</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München , Campus Großhadern</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kreisklinikum Siegen</name>
      <address>
        <city>Siegen</city>
        <zip>57076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwarzwald-Baar Klinikum</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>October 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2017</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-valvular AF</keyword>
  <keyword>ACS</keyword>
  <keyword>PCI</keyword>
  <keyword>NOAC</keyword>
  <keyword>Rivaroxaban</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>An intermediate report summarizing the baseline data will be provided to Bayer (financial support).&#xD;
A final report summarizing baseline and follow-up data will be provided to ethical committees in Germany, to governmental authority, and to Bayer.&#xD;
Participating clinics will receive benchmarking reports (comparison of their own data with those of all other sites).&#xD;
Data will be made accessible to participating investigators for publication in journals and on conferences.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

